Prostatype Genomics publishes Annual Report for 2022

Prostatype Genomics AB today publishes the Annual Report for the financial year of 2021. The Annual Report is attached as a PDF and is available on the company's webpage: www.prostatypegenomics.com

The company is the result of over fifteen years of research work in the genomics of prostate cancer. The company was founded in 2007 as a spin-off from Cancer Center Karolinska (Karolinska Institutet, Stockholm). The result was the development of the today CE-marked and market-ready product Prostatype® Test System. Prostatype® is a test for the prognosis of prostate cancer that has been developed to provide the additional information that is often required to select the optimal treatment strategy for each patient. The test analyses the expression of genes in cancer cells from prostate tissue and which in combination with an advanced algorithm and data analysis provides decision support for optimal treatment of individual patients when prostate cancer has been confirmed. Using AI (artificial intelligence) technology, the Prostatype Genomics genetic test makes it possible to better predict prostate cancer and categorize the patient's condition into different types of risk. In this way, the test can reduce the risk of overtreatment or undertreatment, which in many cases leads to major problems for the patient. Prostatype® is currently the only genetic test for prostate cancer available in kit format.

Nicklas Rosendal

Press contact
nicklas.rosendal@prostatypegenomics.com

Certified Advisor

Svensk Kapitalmarknadsgranskning AB, 011-32 30 732, ca@skmg.se

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.